BASF offer was rejected. Evonik stock sat 4.24 percent below EUR 22.15

Published on 10/12/2026 at 09:04 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Deutsche Bank projected EUR 640.00 million for Evonik's third quarter. Evonik stock costs EUR 21.21 on October 12, 2026 versus the Xetra close of EUR 21.36.

Key points in brief

BASF's EUR 22.15 offer for Evonik was rejected, according to a report dated October 9, 2026.
Evonik stock was EUR 21.21 at Lang & Schwarz on October 12, 2026, 0.70 percent below the October 9 Xetra close.
Deutsche Bank projected EUR 640.00 million in third-quarter operating profit before depreciation, interest, taxes and amortization.
Evonik is listed on Xetra under EVK and is a member of the MDAX.

Fotorealistisches Luftbild eines Spezialchemiewerks mit Destillationstürmen bei Sonnenuntergang — Evonik Industries DE000EVNK013 zeigt ein fotorealistisches Luftbild eines großen Spezialchemiewerks bei Abenddämmerung, Illustration mit AI erstellt.

Evonik (ISIN DE000EVNK013) was trading at EUR 21.21 at Lang & Schwarz on October 12, 2026 at 9:01 a.m. CEST, 4.24 percent below the EUR 22.15 BASF offer that the RAG Stiftung rejected on October 9, 2026, according to DZ Bank. The current price was 0.70 percent below the Xetra close of EUR 21.36 from October 9, 2026.

EUR 22.15 offer sets the reference

The RAG Stiftung, Evonik's largest shareholder, reviewed BASF's takeover approach on October 9, 2026. The reported offer would have valued all Evonik shares at more than EUR 10.30 billion, but the proposal was rejected, according to DZ Bank.

The offer level remains above the Lang & Schwarz price by EUR 0.94 per share. That gap is the clearest market comparison in the takeover discussion, while the RAG Stiftung's reported 43.00 percent holding gives the shareholder a central role in any future process.

Analysts separate deal hope from operations

FinanzNachrichten reported on October 1, 2026 that Deutsche Bank Research kept a Hold rating and an EUR 18.00 target for Evonik. Analyst Virginie Boucher-Ferte projected EUR 640.00 million of third-quarter operating profit before depreciation, interest, taxes and amortization, slightly above consensus and in line with company objectives.

Parmantier & Cie. published a Hold rating and an EUR 20.50 target on October 6, 2026, according to FinanzNachrichten. Both targets sit below the reported BASF offer, showing how takeover expectations have moved beyond the operating forecasts used in standard research.

What dates matter for Evonik?

Evonik's investor-relations calendar sets third-quarter reporting for November 3, 2026 and fourth-quarter reporting for March 4, 2027, according to Evonik. The November report will provide the next operating figure against the EUR 640.00 million estimate.

Stock stays below the offer level

At EUR 21.21, the stock stood below both the EUR 22.15 reported offer and the EUR 21.64 52-week high, while its market capitalization was EUR 10.0 billion as of October 9, 2026. The price was EUR 8.72 above the EUR 12.49 52-week low.

The further course of trading is shown by the continuously updated real-time quote of Evonik stock.